{"hands_on_practices": [{"introduction": "Diagnosing some cancers can be like solving a puzzle, especially when tumors lose their typical appearance. This practice explores how pathologists use immunohistochemistry (IHC), a technique that uses antibodies to 'stain' specific proteins, to identify a tumor's true origin. By tackling the case of a diagnostically challenging desmoplastic melanoma, you will learn the critical difference between lineage markers (which indicate cell origin) and differentiation markers (which indicate cell maturity), a key principle in modern cancer diagnostics [@problem_id:4835766].", "problem": "A clinician biopsies a firm, amelanotic plaque on the shoulder of a patient aged 72 years with chronically sun-damaged skin. Histology reveals a predominantly spindle-cell proliferation set in dense collagen (desmoplasia) with focal perineural infiltration. Immunohistochemistry (IHC; immunohistochemical staining) shows diffuse S100 protein positivity and strong nuclear SRY-related HMG-box 10 (SOX10) positivity, but complete absence of staining for Melan-A (also known as MART-1) and human melanoma black 45 (HMB-45). Broad-spectrum cytokeratin (AE1/AE3) and p63/p40 are negative. The laboratory currently uses a stepwise diagnostic algorithm for spindle-cell cutaneous neoplasms that screens with Melan-A and, if negative, triages cases away from a melanocytic workup.\n\nUsing fundamental principles that immunohistochemical markers reflect lineage and differentiation state, and that tumor progression may downregulate differentiation-associated antigens while retaining lineage transcription factors or broader lineage markers, which of the following best explains why desmoplastic melanoma can be S100 positive but Melan-A negative, and what is the most appropriate implication for diagnostic algorithms?\n\nA. S100 is a sensitive neural crest lineage marker retained in dedifferentiated melanocytic tumors, whereas Melan-A is a melanocyte differentiation antigen often downregulated when melanoma adopts a fibroblast-like, desmoplastic phenotype; algorithms should prioritize sensitive lineage markers (S100, SOX10) up front for spindle-cell lesions and must not exclude melanoma solely on Melan-A negativity, supplementing with cytokeratin and p63/p40 to exclude squamous cell carcinoma.\n\nB. S100 positivity is too nonspecific to be useful and should be disregarded; Melan-A and HMB-45 are the only reliable melanocytic markers, so algorithms should exclude melanoma if both Melan-A and HMB-45 are negative.\n\nC. The profile is more consistent with malignant peripheral nerve sheath tumor (MPNST) because desmoplastic melanoma typically retains Melan-A; algorithms should prioritize S100 and loss of histone H3 lysine 27 trimethylation (H3K27me3) to confirm MPNST.\n\nD. The findings reflect keratin-poor spindle cell squamous cell carcinoma (SCC) because S100 can be upregulated in poorly differentiated carcinomas; algorithms should rely on p40 positivity rather than S100 or SOX10 to confirm the diagnosis.\n\nE. The discrepancy is most likely due to fixation or antigen retrieval artifact selectively affecting Melan-A; algorithms should mandate repeating Melan-A on every S100-positive spindle lesion before considering additional markers or alternative lineages.", "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded, well-posed, and objective. The clinical, histological, and immunohistochemical data provided are internally consistent and accurately represent a classic case of desmoplastic melanoma. The question posed relates directly to fundamental principles of tumor biology and diagnostic pathology.\n\nThe core of this problem lies in understanding the hierarchy of protein expression in neoplasia, specifically the distinction between lineage-defining markers and differentiation-associated markers. The problem statement explicitly directs us to use this principle.\n\n**Derivation from First Principles**\n\n1.  **Lineage vs. Differentiation:** Tumor cells originate from a specific cell type and thus belong to a particular cellular lineage (e.g., melanocytic, epithelial, lymphoid). Markers that are fundamental to the establishment and maintenance of this lineage, such as key transcription factors, are often retained even in poorly differentiated or dedifferentiated tumors. In contrast, markers associated with the specialized functions of a mature, differentiated cell (e.g., producing melanin, keratin, or mucin) may be lost as the tumor becomes more anaplastic.\n\n2.  **Analysis of Immunohistochemical Markers:**\n    *   **S100 Protein and SOX10:** Melanocytes are derived from the neural crest. S100 protein is a sensitive marker for cells of neural crest origin. SOX10 (SRY-related HMG-box 10) is a nuclear transcription factor that is essential for the specification and development of the neural crest and its derivatives, including melanocytes. It is therefore a highly specific and sensitive *lineage* marker. Its strong, diffuse nuclear positivity is compelling evidence for melanocytic lineage.\n    *   **Melan-A and HMB-45:** Melan-A (also known as MART-1) and the antigen recognized by the HMB-45 antibody (gp100) are proteins associated with melanosomes, the organelles responsible for synthesizing and storing melanin. Their expression is directly tied to melanocytic *differentiation* and the functional capacity to produce melanin.\n    *   **Cytokeratin (AE1/AE3) and p63/p40:** Broad-spectrum cytokeratins (AE1/AE3) are markers of epithelial lineage, characteristic of carcinomas. p63 and its more specific isoform p40 are markers of squamous differentiation, characteristic of squamous cell carcinoma (SCC).\n\n3.  **Application to the Case:** The tumor is a spindle-cell proliferation. The differential diagnosis for such a lesion on sun-damaged skin primarily includes spindle cell melanoma, spindle cell squamous cell carcinoma, and atypical fibroxanthoma, with malignant peripheral nerve sheath tumor (MPNST) being a less common consideration.\n    *   The tumor cells are strongly positive for S100 and SOX10. This firmly places the tumor within the melanocytic lineage, as SOX10 is a master regulator of this lineage.\n    *   The tumor cells are negative for Melan-A and HMB-45. This indicates a loss of differentiation markers.\n    *   Desmoplastic melanoma is a specific subtype of melanoma characterized by spindle-shaped, fibroblast-like tumor cells that induce a dense collagenous stroma (desmoplasia). This phenotype represents a form of dedifferentiation. The tumor cells lose the typical morphological and functional characteristics of melanocytes, including the expression of melanosomal proteins.\n    *   Therefore, the immunophenotype—positive for lineage markers (S100, SOX10) but negative for differentiation markers (Melan-A, HMB-45)—is the archetypal signature of desmoplastic melanoma. It reflects the retention of the fundamental melanocytic identity (SOX10) while having lost the specialized machinery of a mature melanocyte (Melan-A).\n    *   The negativity for cytokeratin (AE1/AE3) and p63/p40 effectively rules out a spindle cell squamous cell carcinoma.\n\n4.  **Implications for Diagnostic Algorithm:** A diagnostic algorithm for spindle cell neoplasms that uses Melan-A as an initial screen is fundamentally flawed. Because desmoplastic melanoma is frequently ($>50\\%$ of cases) negative for Melan-A and HMB-45, such an algorithm will systematically fail to identify these aggressive tumors. A robust and safe algorithm must begin with sensitive lineage markers. For a spindle cell tumor, a panel must include markers for melanoma (S100, SOX10), carcinoma (pan-cytokeratin, p40), and potentially other mesenchymal lineages as clinically indicated. The exclusion of melanoma must not be based on the absence of differentiation markers alone.\n\n**Evaluation of Options**\n\n*   **A. S100 is a sensitive neural crest lineage marker retained in dedifferentiated melanocytic tumors, whereas Melan-A is a melanocyte differentiation antigen often downregulated when melanoma adopts a fibroblast-like, desmoplastic phenotype; algorithms should prioritize sensitive lineage markers (S100, SOX10) up front for spindle-cell lesions and must not exclude melanoma solely on Melan-A negativity, supplementing with cytokeratin and p63/p40 to exclude squamous cell carcinoma.**\n    This statement accurately describes the biology of the markers, correctly applies it to the pathophysiology of desmoplastic melanoma, and draws the correct conclusion regarding the necessary changes to the diagnostic algorithm. The inclusion of markers to exclude SCC (p63/p40, cytokeratin) is also appropriate.\n    **Verdict: Correct.**\n\n*   **B. S100 positivity is too nonspecific to be useful and should be disregarded; Melan-A and HMB-45 are the only reliable melanocytic markers, so algorithms should exclude melanoma if both Melan-A and HMB-45 are negative.**\n    This statement is factually incorrect on multiple counts. S100 is an extremely sensitive, albeit not perfectly specific, marker and is indispensable in this context. SOX10 is a more reliable lineage marker than Melan-A or HMB-45. The proposed algorithm is dangerous as it would ensure misdiagnosis of desmoplastic melanoma.\n    **Verdict: Incorrect.**\n\n*   **C. The profile is more consistent with malignant peripheral nerve sheath tumor (MPNST) because desmoplastic melanoma typically retains Melan-A; algorithms should prioritize S100 and loss of histone H3 lysine 27 trimethylation (H3K27me3) to confirm MPNST.**\n    This statement is incorrect. The premise that desmoplastic melanoma \"typically retains Melan-A\" is false; the opposite is true. While MPNST is S100-positive, strong and diffuse SOX10 positivity is a hallmark of desmoplastic melanoma and is much less common or is patchy in MPNST. Thus, the profile is far more consistent with desmoplastic melanoma. While loss of H3K27me3 is a marker for MPNST, it is irrelevant to the primary diagnosis here, which is strongly supported by the existing data.\n    **Verdict: Incorrect.**\n\n*   **D. The findings reflect keratin-poor spindle cell squamous cell carcinoma (SCC) because S100 can be upregulated in poorly differentiated carcinomas; algorithms should rely on p40 positivity rather than S100 or SOX10 to confirm the diagnosis.**\n    This is incorrect. The tumor is explicitly stated to be negative for broad-spectrum cytokeratin (AE1/AE3) and p63/p40. A diagnosis of SCC is untenable in the absence of these epithelial/squamous markers. Furthermore, the combination of diffuse S100 and strong SOX10 positivity is not a feature of SCC.\n    **Verdict: Incorrect.**\n\n*   **E. The discrepancy is most likely due to fixation or antigen retrieval artifact selectively affecting Melan-A; algorithms should mandate repeating Melan-A on every S100-positive spindle lesion before considering additional markers or alternative lineages.**\n    This is an unlikely explanation. The given immunoprofile is not a \"discrepancy\" but the classic, expected pattern for desmoplastic melanoma. Attributing this consistent biological pattern to a technical artifact is not logical. The proposed algorithm is inefficient and misguided, as it focuses on repeating a test for a marker that is biologically downregulated in this tumor type, instead of employing a more comprehensive and informative panel.\n    **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4835766"}, {"introduction": "Once a cancer like melanoma is diagnosed, the next critical question is 'how aggressive is it?' This is answered through staging, a standardized process that classifies a tumor based on its characteristics to predict prognosis and guide therapy. In this exercise, you will step into the role of an oncologist or pathologist and apply the American Joint Committee on Cancer (AJCC) TNM staging system—the global standard—to a real-world melanoma case. You will translate key pathological findings, such as tumor thickness and lymph node status, into a precise prognostic stage [@problem_id:4835790].", "problem": "A patient is diagnosed with cutaneous melanoma. At wide local excision, the Breslow thickness (the maximal vertical depth of the primary melanoma measured from the top of the granular layer to the deepest point of invasion) is measured as $2.1$ $\\mathrm{mm}$. Histopathology documents ulceration of the primary lesion. A sentinel lymph node (the first draining lymph node identified by lymphatic mapping) biopsy is performed and shows metastatic melanoma in exactly one node, detected only by histopathology without prior clinical or radiologic detection. Staging imaging finds no evidence of distant metastasis and there are no in-transit or satellite metastases.\n\nUsing the current American Joint Committee on Cancer (AJCC) eighth edition staging criteria for melanoma, determine the AJCC tumor-node-metastasis code. Express your final AJCC code as a single symbolic expression of the form $T_{\\alpha}N_{\\beta}M_{\\gamma}$ with appropriate numeric indices and suffixes (for example, $T_{1a}$, $N_{1a}$, $M_{0}$). No rounding is required.", "solution": "The problem requires the determination of the American Joint Committee on Cancer (AJCC) eighth edition tumor-node-metastasis (TNM) staging code for a patient with cutaneous melanoma, based on a set of provided clinical and pathological findings. The determination of the TNM code involves a systematic evaluation of the primary tumor (T), regional lymph nodes (N), and distant metastasis (M) categories.\n\n1.  **Determination of the T Category (Primary Tumor)**\n\nThe T category for cutaneous melanoma under the AJCC 8th edition is defined primarily by the Breslow thickness (the maximal vertical depth of invasion) and the presence or absence of ulceration.\n\nThe problem provides the following information for the T category:\n- Breslow thickness: $2.1$ mm.\n- Presence of ulceration: \"Histopathology documents ulceration of the primary lesion.\"\n\nThe AJCC 8th edition criteria for T categories are as follows:\n- $T_{1}$: Tumor thickness $\\le 1.0$ mm.\n- $T_{2}$: Tumor thickness $> 1.0$ mm but $\\le 2.0$ mm.\n- $T_{3}$: Tumor thickness $> 2.0$ mm but $\\le 4.0$ mm.\n- $T_{4}$: Tumor thickness $> 4.0$ mm.\n\nThe given Breslow thickness is $2.1$ mm. This value satisfies the condition for the $T_{3}$ category, as $2.0 < 2.1 \\le 4.0$.\n\nFurthermore, the T categories are sub-classified based on the presence of ulceration:\n- Suffix 'a' indicates no ulceration.\n- Suffix 'b' indicates the presence of ulceration.\n\nThe problem explicitly states that ulceration is present. Therefore, the suffix 'b' is applied to the T category.\n\nCombining the thickness-based category ($T_{3}$) with the ulceration-based suffix ('b'), the correct T category is $T_{3b}$.\n\n2.  **Determination of the N Category (Regional Lymph Nodes)**\n\nThe N category is determined by the number of metastatic regional lymph nodes, whether the metastases are detected clinically (macroscopic) or only on pathology (microscopic/occult), and the presence of in-transit, satellite, or microsatellite metastases.\n\nThe problem provides the following information for the N category:\n- Number of metastatic nodes: \"metastatic melanoma in exactly one node\".\n- Method of detection: \"detected only by histopathology without prior clinical or radiologic detection\". This signifies microscopic or occult nodal disease, often identified via sentinel lymph node biopsy.\n- Presence of other metastases: \"no in-transit or satellite metastases\".\n\nThe AJCC 8th edition criteria for the relevant N categories are:\n- $N_{0}$: No regional lymph node metastases.\n- $N_{1}$: Metastasis in one lymph node; or in-transit, satellite, or microsatellite metastases with no regional lymph node metastases.\n  - $N_{1a}$: One clinically occult (i.e., microscopic) lymph node metastasis.\n  - $N_{1b}$: One clinically detected (i.e., macroscopic) lymph node metastasis.\n  - $N_{1c}$: No regional lymph node metastases, but presence of in-transit, satellite, or microsatellite metastases.\n- $N_{2}$: Metastasis in two or three lymph nodes, or other combinations.\n\nThe patient has metastasis in exactly one lymph node, which points to an $N_{1}$ category. The metastasis was detected \"only by histopathology,\" which is the definition of clinically occult disease. This specifies the sub-category as 'a'. The absence of in-transit or satellite metastases further confirms that the staging is not complicated by the 'c' designator.\n\nTherefore, the correct N category is $N_{1a}$.\n\n3.  **Determination of the M Category (Distant Metastasis)**\n\nThe M category describes the presence or absence of distant metastases, i.e., spread to distant skin, lymph nodes, or internal organs.\n\nThe problem provides the following information for the M category:\n- \"Staging imaging finds no evidence of distant metastasis.\"\n\nThe AJCC 8th edition criteria for the M category are straightforward:\n- $M_{0}$: No evidence of distant metastasis.\n- $M_{1}$: Evidence of distant metastasis.\n\nSince there is no evidence of distant metastasis, the correct M category is $M_{0}$.\n\n4.  **Final Assembly of the TNM Code**\n\nBy combining the individual categories determined above, the complete AJCC TNM code is formed.\n\n- T Category: $T_{3b}$\n- N Category: $N_{1a}$\n- M Category: $M_{0}$\n\nThe final TNM code is the concatenation of these components.", "answer": "$$\\boxed{T_{3b}N_{1a}M_{0}}$$", "id": "4835790"}, {"introduction": "Moving from the individual patient to the health of an entire population requires a different set of tools. We know that ultraviolet ($UV$) radiation is a primary cause of skin cancers like squamous cell carcinoma ($SCC$), but how do we measure its impact on a community? This practice introduces the concept of the Population Attributable Fraction ($PAF$), an essential metric in epidemiology that quantifies the proportion of disease cases in a population that can be attributed to a specific risk factor. By calculating the $PAF$ for $UV$ exposure, you will connect the molecular pathophysiology of skin cancer to its larger public health implications [@problem_id:4835729].", "problem": "A public health team in a sun-intense coastal region is modeling the burden of cutaneous Squamous Cell Carcinoma (SCC) attributable to ultraviolet (UV) radiation exposure. From a mechanistic standpoint, cumulative UV exposure induces cyclobutane pyrimidine dimers and 6-4 photoproducts in keratinocytes, leading to characteristic tumor protein p53 (TP53) UV-signature mutations that increase malignant transformation risk. In the adult population, UV exposure is stratified into three mutually exclusive categories relative to a low-exposure reference: low (reference), moderate, and high. Let the reference category have a relative risk of SCC of $1$ by definition. Assume the following are accurate and apply to SCC incidence over a specified period in a stable population:\n- The prevalence of moderate exposure is $p_{\\mathrm{mod}} = 0.4$ and the prevalence of high exposure is $p_{\\mathrm{high}} = 0.2$, so the prevalence of the low-exposure reference category is $p_{\\mathrm{low}} = 1 - p_{\\mathrm{mod}} - p_{\\mathrm{high}}$.\n- The causal relative risk for SCC is $RR_{\\mathrm{mod}} = 2.0$ for moderate exposure and $RR_{\\mathrm{high}} = 5.0$ for high exposure, each relative to the low-exposure reference.\n- Let $I_{0}$ denote the baseline SCC incidence that would apply to everyone if all were in the low-exposure reference category, and let the observed population incidence be the prevalence-weighted sum of stratum-specific incidences.\n- Assume no uncontrolled confounding, effect modification, or competing risk alterations, and assume the relative risks transport directly to incidence in this population.\n\nUsing only fundamental epidemiological definitions (for example, defining the population attributable fraction as the proportion of the observed population incidence that would be eliminated if the exposure were set to the low-exposure reference in everyone), derive the expression for the population attributable fraction of SCC due to UV exposure across the moderate and high exposure categories, and then compute its value using the parameters above. Express your final result as a decimal fraction with no unit and round your answer to four significant figures.", "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n**1. Extraction of Givens:**\n- Exposure categories: low (reference), moderate, high.\n- Prevalence of moderate exposure: $p_{\\mathrm{mod}} = 0.4$.\n- Prevalence of high exposure: $p_{\\mathrm{high}} = 0.2$.\n- Prevalence of low exposure: $p_{\\mathrm{low}} = 1 - p_{\\mathrm{mod}} - p_{\\mathrm{high}}$.\n- Relative risk for moderate exposure vs. low: $RR_{\\mathrm{mod}} = 2.0$.\n- Relative risk for high exposure vs. low: $RR_{\\mathrm{high}} = 5.0$.\n- Relative risk for low exposure (reference): $RR_{\\mathrm{low}} = 1$.\n- Baseline incidence in the low-exposure category: $I_{0}$.\n- Observed population incidence ($I_{\\text{obs}}$): defined as the prevalence-weighted sum of stratum-specific incidences.\n- Core assumption: Population Attributable Fraction (PAF) is the proportion of observed incidence eliminated if the entire population adopted the low-exposure (reference) level.\n- Supporting assumptions: No uncontrolled confounding, effect modification, or other biases.\n\n**2. Validation Verdict:**\nThe problem is deemed **valid**. It is scientifically grounded in established epidemiological principles, using standard definitions for prevalence, relative risk, and population attributable fraction. The provided data are complete, internally consistent, and sufficient to derive a unique solution. The problem is well-posed and objective, presenting a formalizable scenario without ambiguity or factual inaccuracies.\n\n**3. Solution Derivation:**\nThe problem requires the derivation and calculation of the population attributable fraction (PAF) for Squamous Cell Carcinoma (SCC) due to moderate and high UV exposure.\n\nFirst, we formalize the relationship between stratum-specific incidence, baseline incidence $I_{0}$, and relative risk ($RR$). The incidence in an exposure stratum $j$ ($I_j$) is given by the product of the reference incidence $I_0$ and the relative risk for that stratum $RR_j$.\n- Incidence in low-exposure stratum: $I_{\\mathrm{low}} = RR_{\\mathrm{low}} \\cdot I_{0} = 1 \\cdot I_{0} = I_{0}$.\n- Incidence in moderate-exposure stratum: $I_{\\mathrm{mod}} = RR_{\\mathrm{mod}} \\cdot I_{0}$.\n- Incidence in high-exposure stratum: $I_{\\mathrm{high}} = RR_{\\mathrm{high}} \\cdot I_{0}$.\n\nThe observed population incidence, $I_{\\text{obs}}$, is the prevalence-weighted average of the stratum-specific incidences:\n$$I_{\\text{obs}} = p_{\\mathrm{low}} I_{\\mathrm{low}} + p_{\\mathrm{mod}} I_{\\mathrm{mod}} + p_{\\mathrm{high}} I_{\\mathrm{high}}$$\nSubstituting the expressions for each $I_j$ in terms of $I_0$:\n$$I_{\\text{obs}} = p_{\\mathrm{low}}(I_{0}) + p_{\\mathrm{mod}}(RR_{\\mathrm{mod}} \\cdot I_{0}) + p_{\\mathrm{high}}(RR_{\\mathrm{high}} \\cdot I_{0})$$\nFactoring out the baseline incidence $I_{0}$:\n$$I_{\\text{obs}} = I_{0} (p_{\\mathrm{low}} + p_{\\mathrm{mod}} RR_{\\mathrm{mod}} + p_{\\mathrm{high}} RR_{\\mathrm{high}})$$\n\nThe population attributable fraction (PAF) is defined as the proportion of cases that would be prevented if the risk factor were eliminated. In this context, \"elimination\" means setting the exposure for the moderate and high groups to the low-exposure reference level.\nThe incidence in this counterfactual scenario, where the entire population experiences the low-exposure risk, would be $I_{0}$. The number of cases attributable to the exposure is the difference between the observed cases and the counterfactual cases, which is proportional to $I_{\\text{obs}} - I_{0}$. The PAF is the ratio of these attributable cases to the total observed cases:\n$$PAF = \\frac{I_{\\text{obs}} - I_{0}}{I_{\\text{obs}}}$$\nThis can be rewritten as:\n$$PAF = 1 - \\frac{I_{0}}{I_{\\text{obs}}}$$\nSubstituting our derived expression for $I_{\\text{obs}}$:\n$$PAF = 1 - \\frac{I_{0}}{I_{0} (p_{\\mathrm{low}} + p_{\\mathrm{mod}} RR_{\\mathrm{mod}} + p_{\\mathrm{high}} RR_{\\mathrm{high}})}$$\nThe term $I_{0}$ cancels out, demonstrating that the PAF is independent of the baseline incidence:\n$$PAF = 1 - \\frac{1}{p_{\\mathrm{low}} + p_{\\mathrm{mod}} RR_{\\mathrm{mod}} + p_{\\mathrm{high}} RR_{\\mathrm{high}}}$$\nBy finding a common denominator, we get the final expression for the PAF:\n$$PAF = \\frac{(p_{\\mathrm{low}} + p_{\\mathrm{mod}} RR_{\\mathrm{mod}} + p_{\\mathrm{high}} RR_{\\mathrm{high}}) - 1}{p_{\\mathrm{low}} + p_{\\mathrm{mod}} RR_{\\mathrm{mod}} + p_{\\mathrm{high}} RR_{\\mathrm{high}}}$$\nThis expression represents the excess population risk (numerator) as a fraction of the total population risk (denominator), where risk is measured relative to the reference group.\n\nNow, we compute the value of the PAF using the given parameters.\nFirst, we calculate the prevalence of the low-exposure group:\n$$p_{\\mathrm{low}} = 1 - p_{\\mathrm{mod}} - p_{\\mathrm{high}} = 1 - 0.4 - 0.2 = 0.4$$\nNext, we calculate the denominator of the PAF expression, which is the prevalence-weighted average relative risk for the population:\n$$\\text{Denominator} = p_{\\mathrm{low}}(RR_{\\mathrm{low}}) + p_{\\mathrm{mod}} RR_{\\mathrm{mod}} + p_{\\mathrm{high}} RR_{\\mathrm{high}}$$\nSubstituting the values:\n$$\\text{Denominator} = (0.4)(1) + (0.4)(2.0) + (0.2)(5.0)$$\n$$\\text{Denominator} = 0.4 + 0.8 + 1.0 = 2.2$$\nNow, we calculate the numerator:\n$$\\text{Numerator} = \\text{Denominator} - 1 = 2.2 - 1 = 1.2$$\nFinally, we compute the PAF:\n$$PAF = \\frac{\\text{Numerator}}{\\text{Denominator}} = \\frac{1.2}{2.2} = \\frac{12}{22} = \\frac{6}{11}$$\nAs a decimal fraction, this is:\n$$PAF \\approx 0.545454...$$\nRounding to four significant figures as required by the problem statement gives:\n$$PAF \\approx 0.5455$$\nThis means that approximately $54.55\\%$ of the SCC cases in this population are attributable to having moderate or high UV exposure compared to the low-exposure reference level.", "answer": "$$\\boxed{0.5455}$$", "id": "4835729"}]}